Top of this page
Skip navigation, go straight to the content

Investors Overview

At UCB,
we aspire to be the patient-preferred biotech leader. 

To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.

Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.

In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success. 

2018 FY results

Business general picture

 

UCB will publish its 2018 full year results on Thursday 28 February 2019.

More details closer to the date.

 

IR events

DateEvent details
12 December
2018
Exane Healthcare Leaders Forum, Paris1/1 meetings
18 December
2018
Roadshow in BrusselsBroker: KBC
08 January
2019
JP Morgan 2019 Annual Healthcare Conference, San Francisco1/1 meetings
09 January
2019
JP Morgan 2019 Annual Healthcare Conference, San FranciscoPresentation & 1/1 meetings

Outlook 2018

2018 revenue reporting to reach approximately

€ 4.5-4.6 billion 

Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] in the range of

€ 1.3-1.4 billion 

Core earnings per share are therefore expected in the range of

€ 4.30-4.70

based on an average of
188 million shares outstanding

Contact UCB IR team

investor-relations@ucb.com or a specific team member:

 

UCB IR App

 

UCB IR app available on Apple Store


UCB IR app available on Google Play